Literature DB >> 2834537

Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine.

J S Heyman1, C L Williams, T F Burks, H I Mosberg, F Porreca.   

Abstract

The effect of pretreatment with naloxonazine on opioid-mediated antinociception against a thermal stimulus (55 degrees C warm-water tail-flick test) and inhibition of gastrointestinal transit at supraspinal and spinal levels was studied in unanesthetized mice. The mu-selective agonist [D-Ala2, N-methyl-Phe4, Gly5-ol]enkephalin (DAGO), the delta-selective agonist [D-Pen2, D-Pen5]enkephalin (DPDPE) and the reference mu-acting agonist morphine, all produced antinociception after either i.c.v. or intrathecal(ly) (i.t.) administration. Morphine and DAGO, but not DPDPE, inhibited gastrointestinal transit after i.c.v. administration, whereas all three agonists slowed gut propulsion when given i.t. A single s.c. naloxonazine pretreatment, 35 mg/kg given 24 hr earlier, failed to displace the dose-response line for i.c.v. DPDPE antinociception but produced a marked rightward displacement of the i.c.v. morphine and DAGO dose-response lines for antinociception. In contrast, naloxonazine (35 mg/kg) pretreatment did not alter the antinociceptive effects of i.t. morphine, DAGO or DPDPE. The effects of naloxonazine pretreatment on inhibition of gut propulsion were the converse of those observed for antinociception at supraspinal and spinal sites; naloxonazine had no effect on the antitransit properties of i.c.v. morphine and DAGO but inhibited the antitransit properties of all three agonists when they were given i.t. These results support the view that opioids may produce their supraspinal antitransit effects at a receptor different from that mediating antinociception; morphine and DAGO mediate their antitransit effects at a naloxonazine-insensitive site, whereas their antinociceptive effects are produced at the naloxonazine-sensitive receptor.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2834537

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Splice variation of the mu-opioid receptor and its effect on the action of opioids.

Authors:  Sophy K Gretton; Joanne Droney
Journal:  Br J Pain       Date:  2014-11

Review 2.  Development of delta opioid peptides as nonaddicting analgesics.

Authors:  R S Rapaka; F Porreca
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

Review 3.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 4.  Site and mechanism of morphine tolerance in the gastrointestinal tract.

Authors:  H I Akbarali; A Inkisar; W L Dewey
Journal:  Neurogastroenterol Motil       Date:  2014-10       Impact factor: 3.598

5.  Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.

Authors:  Shaness A Grenald; Madison A Young; Yue Wang; Michael H Ossipov; Mohab M Ibrahim; Tally M Largent-Milnes; Todd W Vanderah
Journal:  Neuropharmacology       Date:  2016-12-20       Impact factor: 5.250

6.  Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects.

Authors:  Susruta Majumdar; Steven Grinnell; Valerie Le Rouzic; Maxim Burgman; Lisa Polikar; Michael Ansonoff; John Pintar; Ying-Xian Pan; Gavril W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-21       Impact factor: 11.205

7.  Inflammation-associated changes in DOR expression and function in the mouse colon.

Authors:  Jesse J DiCello; Ayame Saito; Pradeep Rajasekhar; Emily M Eriksson; Rachel M McQuade; Cameron J Nowell; Benjamin W Sebastian; Jakub Fichna; Nicholas A Veldhuis; Meritxell Canals; Nigel W Bunnett; Simona E Carbone; Daniel P Poole
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-06-21       Impact factor: 4.052

Review 8.  Opioids and their receptors: Are we there yet?

Authors:  Gavril W Pasternak
Journal:  Neuropharmacology       Date:  2013-04-26       Impact factor: 5.250

9.  Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in rats.

Authors:  Caren L Steinmiller; Alice M Young
Journal:  Psychopharmacology (Berl)       Date:  2007-09-19       Impact factor: 4.530

10.  Effect of pretreatment with pertussis toxin on the development of physical dependence on morphine.

Authors:  M Funada; M Narita; T Suzuki; M Misawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.